Tamper-Resistant Multiparticulate Dosage Form via Segmentation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current opioid analgesic dosage forms, particularly controlled-release forms, are vulnerable to abuse due to ease of crushing and solvent extraction, which can lead to rapid drug release and misuse, and are difficult to formulate in high-strength, tamper-resistant, and cost-effective formats that maintain extended release profiles.

Innovation Solution

Melt-extruded particulates of opioid agonists incorporated into a matrix with a gel-forming agent, such as a copolymer of acrylic acid alkyl esters and methacrylic acid alkyl esters, provide crush resistance and resistance to alcohol extraction, forming a dosage form that is difficult to tamper with and maintains controlled drug release.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high molecular weight polyethylene oxide (PEO) is used to control drug release rate and impart crush resistance, then the dosage form gains tamper resistance and crush resistance, but the dosage form becomes too large and heavy for easy administration

Engineering Contradiction:
Improvetamper resistanceVSAvoiddosage form weight
Core Design Contradiction:
ReliabilityVSWeight of stationary object

Solution Approach 1:

The dosage form is segmented into multiple small spherical multiparticulates (0.5-2.0 mm diameter) rather than a single large tablet. Each multiparticulate contains the opioid analgesic and PEO matrix, allowing the total drug dose to be distributed across many small particles that are easier to administer while maintaining the required PEO-to-drug ratio for tamper resistance

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention changes the physical parameters of the dosage form by using spherical multiparticulates with controlled size distribution (0.5-2.0 mm diameter) instead of traditional large tablets. This parameter change maintains the effective PEO concentration for tamper resistance while reducing the overall dosage form size and weight for easier administration

Inventive Principle:
Principle #35Parameter changes

2Duration of action of moving object

If high molecular weight polyethylene oxide (PEO) is used to control drug release rate, then the dosage form gains extended release capability, but the dosage form becomes too large and heavy for easy administration

Engineering Contradiction:
Improvedrug release durationVSAvoiddosage form weight
Core Design Contradiction:
Duration of action of moving objectVSWeight of stationary object

Solution Approach 1:

The extended-release functionality is segmented across multiple small spherical multiparticulates, each containing the opioid and PEO matrix. The collective surface area and matrix structure of numerous small particles provide the required extended release duration (24 hours or more) while keeping individual particle size small for easy administration

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention optimizes the size parameter of the multiparticulates (0.5-2.0 mm diameter) to achieve a balance between extended release duration and ease of administration. The controlled release is maintained through the PEO matrix structure across the multiparticulate system rather than requiring a single large formulation

Inventive Principle:
Principle #35Parameter changes

3Strength

If melt extruded multiparticulates are used to provide crush resistance, then the dosage form gains some crush resistance, but the multiparticulates remain susceptible to abuse by alcohol extraction

Engineering Contradiction:
Improvecrush resistanceVSAvoidalcohol extraction susceptibility
Core Design Contradiction:
StrengthVSObject-affected harmful factors

Solution Approach 1:

The invention uses a composite material system where the PEO matrix (50-90% w/w of total formulation) is combined with the opioid analgesic. The PEO forms a gel structure upon contact with extraction solvents like alcohol, creating a viscous gel that physically resists syringing and injection while also providing the extended-release matrix. This composite approach simultaneously achieves crush resistance and alcohol extraction resistance

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The invention converts the potential harm of alcohol extraction into a beneficial gel-forming response. When alcohol or other extraction solvents contact the PEO matrix, they trigger gel formation that increases viscosity and creates a physical barrier, transforming the extraction attempt into a self-defending mechanism that prevents rapid drug release

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The dosage form exhibits excellent alcohol-extraction resistance and crush resistance, ensuring consistent drug release over an extended period while deterring abuse, as it forms a viscous solution upon alcohol exposure and withstands physical tampering, maintaining therapeutic efficacy while minimizing misuse.

Implementation Method 1

The matrix in which the particulates are present provides resistance to alcohol extraction by forming a gel or viscous solution on exposure to alcohol that resists syringing or injection.

Methodology Applied
Scientific EffectGel formation: Gel

Implementation Method 2

Melt extruded multiparticulates comprising opioid analgesics

Methodology Applied
Scientific EffectMelting: Melting

Implementation Method 3

Melt extruded multiparticulates comprising opioid analgesics are also known

Methodology Applied
Scientific EffectExtrusion: Extrusion

Data Source

PatentEP2437729B1Tamper resistant dosage form comprising a matrix and melt-extruded particulates comprising a drug
Publication Date: 2019.01.23 EURO CELTIQUE SA
  • EP2437729B1 patent drawingFigure 1
  • EP2437729B1 patent drawingFigure 2
  • EP2437729B1 patent drawingFigure 3

AI summary

The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising: melt-extruded particulates comprising a drug; and a matrix; wherein said melt-extruded particulates are present as a discontinuous phase in said matrix.